Analysis of article using Artificial Intelligence tools
|Lin R., Yan Y.-J., Zhou Y., Luo Y.-T., Cai Z.-Z., Zhu K.-Y., Li H.
|Effects of Creative Expressive Arts-based Storytelling (CrEAS) programme on older adults with mild cognitive impairment: Protocol for a randomised, controlled three-arm trial
Lin R., Yan Y.-J., Zhou Y., Luo Y.-T., Cai Z.-Z., Zhu K.-Y., Li H.; Effects of Creative Expressive Arts-based Storytelling (CrEAS) programme on older adults with mild cognitive impairment: Protocol for a randomised, controlled three-arm trial ;BMJ Open vol:10.0 issue: 11 page:
|clinical trials; dementia; magnetic resonance imaging; neurology
|Link to article
|Introduction Early non-pharmacological interventions can prevent cognitive decline in older adults with mild cognitive impairment (MCI). Creative expression (CrExp) can potentially mitigate cognitive decline and enhance the physical and mental health of older people. However, it is unclear whether activities involving CrExp can improve cognitive function and other health-related outcomes in older adults with MCI. The aim of the present study is to develop a Creative Expressive Arts-based Storytelling (CrEAS) programme that integrates verbal and non-verbal expressive activities and evaluate its effectiveness in improving cognitive function and other outcome indicators so as to explore its possible mechanism from the perspective of neuroimaging. Methods and analysis This parallel randomised controlled trial with three arms (one intervention and two control arms) will be conducted over a 24-week period. A total of 111 participants will be enrolled and randomised to the CrEAS, recreation and usual activity groups. The CrEAS programme combines visual arts therapy and storytelling (TimeSlips) under the Expressive Therapy Continuum theoretical framework and provides an opportunity for people with MCI to actively engage in activities to improve cognitive function through verbal and nonverbal CrExp. Global cognitive function, specific domains of cognition (memory, executive function, language and attention) and other health-related outcomes (anxiety, depression and quality of life) will be measured at baseline, at the end of the intervention, and at the 24-week follow-up. Structural/functional brain MRI data will be collected at baseline and immediately after the intervention. Ethics and dissemination Ethics approval was obtained from the Ethics Committee of Fujian Provincial Hospital (K2018-03-061). The study results will be disseminated through peer-reviewed journals and at academic conferences. Trial registration number ChiCTR1900021526. © 2020 BMJ Publishing Group. All rights reserved.